Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Drug Design

Background:

• Previous pentapeptidic and non-peptidic BACE1 inhibitors showed potent activity but were too large for drug development.
• Alzheimer's disease drug development requires inhibitors with reduced molecular weight for practicality.

Purpose of the Study:

• To design and develop novel, lower molecular weight BACE1 inhibitors.
• To explore a new generation of BACE1 inhibitors using in-silico conformational structure-based design.

Main Methods:

• Utilized substrate-based design principles from previous inhibitors.
• Employed in-silico conformational structure-based design to create tripeptidic inhibitors.
• Focused on a hydroxymethylcarbonyl isostere as a substrate transition-state mimic.

Main Results:

• Successfully designed a series of tripeptidic BACE1 inhibitors.
• Achieved significantly lower molecular weight compared to previous lead compounds.
• Identified unique structural features in the new inhibitors.

Conclusions:

• The developed tripeptidic BACE1 inhibitors are promising lead compounds.
• These inhibitors represent a potential advancement for next-generation anti-Alzheimer's disease therapeutics.
• The in-silico design approach yielded inhibitors with desirable low molecular size.